Compare Nvidia Corp (NVDA) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs Repligen Corporation Common Stock — how do they compare? Nvidia Corp trades at $218.51 (market cap $5.52T), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Nvidia Corp is far larger — about 495.5× Repligen Corporation Common Stock's market cap, and Nvidia Corp pays a 0.44% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nvidia Corp for 116 Days and Repligen Corporation Common Stock for 0 Days on average.
| NVDA | RGEN | |
|---|---|---|
Market Cap | $5.52T | $11.14B |
Volume | 84,036,941 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $239.27 | $194.57 |
52-Week Low | $165.17 | $102.87 |
Typical Hold Time | 116 Days | 0 Days |
Enterprise Value | $5.49T | $11.02B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $221.51, down 2.13% today, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $221. Fundamentally, the company reported stellar revenue growth to $130.50 billion in 2025 and a net income margin of 63.66%, though valuation ratios like a P/E of 28.89 and P/S of 18.4 remain elevated. Recent news highlights AI-driven growth potential but also concerns over market saturation.
Outlook: Strong AI demand and earnings beats support long-term growth, but high valuations and competitive pressures pose risks. Analyst consensus is bullish with a $339.17 price target, suggesting significant upside if execution continues.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
